Genomics of HIV/AIDS Drug Response and Co-Morbidities (R01) | PA 16 435

Opportunity Information: Apply for PA 16 435

The Genomics of HIV/AIDS Drug Response and Co-Morbidities (R01) funding opportunity (PA-16-435) is a National Institutes of Health (NIH) research grant focused on using modern genomic tools to improve how HIV/AIDS is treated and how related health problems are prevented or managed. The core aim is to expand the use of high-throughput genotyping, genomic sequencing, and other genomic technologies in order to understand why people respond differently to HIV therapies and to other medications commonly used in people living with HIV. A central theme is generating genomic and related datasets that can be made broadly available to the research community, so that findings are not limited to a single study team but can be reused and built upon to accelerate progress across the field.

This opportunity emphasizes practical, patient-centered outcomes tied to precision medicine for HIV. That includes improving the efficacy of HIV/AIDS therapies (helping more patients achieve strong viral suppression and durable treatment success), improving safety (reducing toxicities and serious adverse drug reactions), and improving ease of use (supporting more tolerable and simpler regimens that promote long-term adherence). It also explicitly includes studying non-HIV drugs used in HIV/AIDS patients, reflecting the reality that many people living with HIV take medications for other conditions and may experience important drug-gene interactions, drug-drug interactions, or unique toxicity risks.

Another major objective is reducing HIV/AIDS-related comorbidities, coinfections, and complications through genomics-informed research. In practice, this can involve investigating genetic and genomic factors that influence vulnerability to, or outcomes from, conditions that commonly co-occur with HIV, as well as complications that arise from long-term infection, chronic inflammation, or extended exposure to therapy. By tying genomic variation to clinical outcomes, researchers can identify biomarkers, risk predictors, and mechanistic pathways that could eventually guide individualized treatment selection, monitoring strategies, or preventive interventions.

The award mechanism is an R01, meaning it supports full-scale, investigator-initiated research projects in health-related science. The opportunity is categorized as discretionary funding and falls under the health funding activity category, with CFDA number 93.172. While the listing notes an original closing date of 2020-05-07 and does not specify an award ceiling or expected number of awards in the provided text, the scientific purpose is clearly oriented toward producing high-value genomic resources and actionable insights into medication response and HIV-associated health burdens.

Eligibility is broad and includes many types of U.S. domestic applicants such as state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (including those other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses. The announcement also highlights additional eligible applicant categories, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with eligible federal agencies, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions.

International participation is allowed in a specific way. Non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) may apply, and non-domestic components of U.S. organizations are eligible to apply. However, foreign components as defined in the NIH Grants Policy Statement are not allowed under this announcement, which is an important boundary for structuring collaborations and determining where work can be formally scoped within the application.

Overall, this FOA targets genomics-driven research that can directly improve treatment decisions and health outcomes for people living with HIV by identifying genetic and genomic contributors to drug response, adverse events, and the broader set of comorbidities and complications that shape long-term quality of life. A distinguishing feature is the expectation that resulting genomic data resources be made widely available, reinforcing NIH priorities around data sharing, reproducibility, and maximizing the public health impact of funded research.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Genomics of HIV/AIDS Drug Response and Co-Morbidities (R01)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172.
• This funding opportunity was created on 2016-09-19.
• Applicants must submit their applications by 2020-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PA 16 435

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: